
In addition, for countries where a nationally representative seroprevalence survey had been conducted (n=44), we include
seroprevalence data in the calibration likelihood. We used the online platform SeroTracker to extract country-specific seroprevalence estimates. 
The estimates had to verify the following conditions to be included in the analysis as calibration targets:
\begin{itemize}
    \item Be aligned with the World Health Organization's Unity protocol (WHO Unity) for general population seroepidemiological studies.
    \item Have a sample size greater than 599 (minimum sample size recommended in \textcolor{blue}{\href{https://docs.google.com/document/d/1NYpszkr-u__aZspFDFa_fa4VBzjAAAAxNxM1rZ1txWU/edit}{WHO sero-surveys protocol}})
    \item Have a sampling start date later than 1 May 2020 (to avoid very early surveys that may be less accurate)
    \item Be nationally representative (as classified by SeroTracker)
\end{itemize}

We further excluded studies that focused on specific population subgroups presenting a risk of selection bias for seroprevalence (e.g. pregnant women, slum population, healthcare workers, quarantine workers). 
Finally, to minimise the risk of interference with vaccination, we only included studies for which the vaccination coverage at the time of the survey (midpoint date) 
was lower than 10\% of the measured seroprevalence.

All the criteria listed above were first verified systematically using the SeroTracker database, and the extracted studies were then analysed individually by one author (RR) to check 
that all inclusion criteria were verified.

When a seroprevalence study was restricted to a specific age-group, we matched the survey estimate to the modelled seroprevalence measured in the 
closest modelled age-group. For example, as the age-group reported in the Kenya survey was 16-64 years old, we used the modelled seroprevalence 
in the age-group 15-69 years-old to inform model calibration. 

When multiple estimates were available for a country, we selected the highest ranked estimate after ordering by the following preference criteria (applied in the presented order):
\begin{enumerate}
    \item Lowest risk of bias (according to SeroTracker),
    \item Latest sampling start date (when a greater number of infections have occurred, and to avoid bias due to early geographic heterogeneity),
    % \item Largest sample size.
\end{enumerate}

The estimates used to inform the models are summarised in Table \ref{tab:sero_national}, with the associated original reports accessible by clicking on the countries' names.

\begin{table}[!ht]  
    \footnotesize
    \begin{center}
        \caption{Seroprevalence data extracted from SeroTracker (national surveys).}
        \label{tab:sero_national}
        \begin{tabular}{p{2cm} | p{1.6cm} | p{1.6cm} | p{0.8cm} | p{0.8cm} | p{1cm} | p{1.3cm} | p{1.2cm} | p{1.2cm}}
           \hline            
           \textbf{country} & \textbf{sampling start date} & \textbf{sampling end date} & \textbf{age min} & \textbf{age max} & \textbf{denom. value} & \textbf{serum pos prevalence} & \textbf{estimate grade} & \textbf{overall risk of bias} \\ 
\hline 
\href{https://dx.doi.org/10.5694/mja2.51542}{\textcolor{blue}{Australia}} & 2020-11-03 & 2021-03-12 &  & 19 & 1685 & 0.23\% & National & High \\ 
\hline 
\href{https://dx.doi.org/10.1007/s15010-021-01639-0}{\textcolor{blue}{Austria}} & 2020-06-05 & 2020-12-04 & 18 & 72 & 20228 & 2.5\% & National & High \\ 
\hline 
\href{https://dx.doi.org/10.2807/1560-7917.ES.2022.27.9.2100419}{\textcolor{blue}{Belgium}} & 2020-10-12 & 2020-10-17 &  & 101 & 2966 & 4.18\% & National & Low \\ 
\hline 
\href{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225319/}{\textcolor{blue}{Brazil}} & 2020-05-14 & 2020-06-23 &  &  & 89362 & 2.3\% & National & Moderate \\ 
\hline 
\href{https://serotracker.com/en/Explore}{\textcolor{blue}{Canada}} & 2021-04-13 & 2021-04-30 & 17 &  & 16931 & 26.92\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.1186/s12879-022-07045-7}{\textcolor{blue}{Chile}} & 2020-09-25 & 2020-11-25 & 7 & 94 & 2493 & 10.4\% & National & Low \\ 
\hline 
\href{https://dx.doi.org/10.1016/j.lana.2022.100195}{\textcolor{blue}{Colombia}} & 2020-09-21 & 2020-12-11 & 5 & 80 & 17863 & 32.53\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.3390/pathogens10060774}{\textcolor{blue}{Croatia}} & 2020-12-15 & 2021-02-15 &  &  & 1436 & 25.1\% & National & High \\ 
\hline 
\href{https://doi.org/10.1038/s43856-022-00080-0}{\textcolor{blue}{Czechia}} & 2021-02-01 & 2021-03-31 & 18 &  & 19548 & 51.0\% & National & High \\ 
\hline 
\href{https://dx.doi.org/10.1007/s10654-021-00796-8}{\textcolor{blue}{Denmark}} & 2020-12-01 & 2020-12-31 & 12 &  & 4044 & 4.3\% & National & Low \\ 
\hline 
\href{https://dx.doi.org/10.3389/fmed.2022.933260}{\textcolor{blue}{Ecuador}} & 2020-10-12 & 2020-10-19 &  &  & 1250 & 11.68\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.1186/s41182-022-00448-x}{\textcolor{blue}{Egypt}} & 2021-01-15 & 2021-06-15 &  &  & 2360 & 46.3\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.1038/s41467-021-23233-6}{\textcolor{blue}{France}} & 2020-05-11 & 2020-05-17 &  &  & 3592 & 4.93\% & National & Low \\ 
\hline 
\href{https://www.ifo.de/en/publikationen/2020/monograph-authorship/die-deutschen-und-corona}{\textcolor{blue}{Germany}} & 2020-10-26 & 2020-11-18 & 18 &  & 9929 & 1.1\% & National & Moderate \\ 
\hline 
\href{https://revistas.ucr.ac.cr/index.php/psm/article/view/43261/46175}{\textcolor{blue}{Honduras}} & 2020-06-16 & 2020-06-23 & 5 &  & 792 & 6.2\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.1007/s11357-020-00226-9}{\textcolor{blue}{Hungary}} & 2020-05-01 & 2020-05-16 & 14 &  & 10474 & 0.68\% & National & Low \\ 
\hline 
\href{http://dx.doi.org/10.1016/j.ijid.2021.05.040}{\textcolor{blue}{India}} & 2020-12-18 & 2021-01-06 & 10 &  & 28598 & 24.1\% & National & Low \\ 
\hline 
\href{https://dx.doi.org/10.1186/s12889-022-13464-7}{\textcolor{blue}{Iran}} & 2021-01-15 & 2021-03-15 & 10 & 90 & 7411 & 34.2\% & National & Low \\ 
\hline 
\href{https://dx.doi.org/10.1007/s10654-021-00749-1}{\textcolor{blue}{Israel}} & 2020-06-28 & 2020-09-14 &  &  & 54357 & 4.6\% & National & Moderate \\ 
\hline 
\href{https://www.istat.it/it/files//2020/08/ReportPrimiRisultatiIndagineSiero.pdf}{\textcolor{blue}{Italy}} & 2020-05-25 & 2020-07-15 &  &  & 64660 & 2.5\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.3201/eid2702.204088}{\textcolor{blue}{Japan}} & 2020-06-01 & 2020-06-07 & 20 &  & 7950 & 0.1\% & National & Moderate \\ 
\hline 
\href{http://dx.doi.org/10.1016/j.onehlt.2021.100292}{\textcolor{blue}{Jordan}} & 2020-12-27 & 2021-01-06 &  &  & 5044 & 34.2\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.3390/ijerph19042263}{\textcolor{blue}{Kazakhstan}} & 2020-07-16 & 2021-07-07 &  &  & 85346 & 63.0\% & National & High \\ 
\hline 
\href{https://dx.doi.org/10.1001/jama.2021.15265}{\textcolor{blue}{Kenya}} & 2021-01-03 & 2021-03-15 & 16 & 64 & 3018 & 48.5\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.1186/s12879-022-07031-z}{\textcolor{blue}{Lebanon}} & 2020-12-07 & 2021-01-15 &  &  & 2058 & 18.5\% & National & Low \\ 
\hline 
\href{https://www.journals.vu.lt/AML/article/view/22344}{\textcolor{blue}{Lithuania}} & 2020-08-10 & 2020-09-10 & 18 & 92 & 3089 & 1.4\% & National & Moderate \\ 
\hline 
\href{https://saludpublica.mx/index.php/spm/article/view/12847}{\textcolor{blue}{Mexico}} & 2020-08-15 & 2020-11-15 & 3 & 12 & 944 & 18.7\% & National & Low \\ 
\hline 
\href{https://mohp.gov.np/attachments/article/708/First%20Sero-prevalence\_final\_report\_04-04-2021.pdf}{\textcolor{blue}{Nepal}} & 2020-10-09 & 2020-10-22 &  &  & 3040 & 14.4\% & National & Low \\ 
\hline 
\href{https://bmjopen.bmj.com/content/12/4/e055381.abstract}{\textcolor{blue}{Pakistan}} & 2020-10-21 & 2020-11-08 &  &  & 4998 & 7.02\% & National & Moderate \\ 
\hline 
\href{https://wwwnc.cdc.gov/eid/article/27/11/21-0636\_article}{\textcolor{blue}{Portugal}} & 2020-09-08 & 2020-10-14 &  &  & 13398 & 2.2\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.1016/j.cmi.2021.03.009}{\textcolor{blue}{Slovenia}} & 2020-10-17 & 2020-11-10 &  & 99 & 1211 & 4.29\% & National & Low \\ 
\hline 
\href{https://assets.researchsquare.com/files/rs-690372/v2\_covered.pdf?c=1627923426}{\textcolor{blue}{South Africa}} & 2021-01-15 & 2021-05-15 & 15 & 69 & 16762 & 47.4\% & National & Moderate \\ 
\hline 
\href{https://bmjopen.bmj.com/content/11/4/e049837.abstract}{\textcolor{blue}{Rep. of Korea}} & 2020-09-24 & 2020-12-09 & 18 & 86 & 4085 & 0.39\% & National & Moderate \\ 
\hline 
\href{https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO\_ENE-COVID19\_INFORME\_FINAL.pdf}{\textcolor{blue}{Spain}} & 2020-06-08 & 2020-06-22 &  &  & 62167 & 5.2\% & National & Low \\ 
\hline 
\href{https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf}{\textcolor{blue}{Sweden}} & 2020-11-23 & 2020-12-04 &  &  & 3183 & 7.0\% & National & Moderate \\ 
\hline 
\href{https://dx.doi.org/10.1093/cid/ciab626}{\textcolor{blue}{USA}} & 2020-08-09 & 2020-12-08 & 18 &  & 4654 & 4.71\% & National & Low \\ 
\hline 
\href{https://www.gov.uk/government/publications/national-covid-19-surveillance-reports}{\textcolor{blue}{UK}} & 2020-08-24 & 2020-09-18 & 17 &  & 8230 & 6.1\% & National & Low \\ 
\hline 


    \end{tabular}
    \end{center}
\end{table}